Patents Examined by Charanjit Aulakh
  • Patent number: 10464904
    Abstract: The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating and preventing diseases and conditions in man and mammals.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 5, 2019
    Assignee: Heinrich-Heine-Universitat Dusseldorf
    Inventors: Eckhard Lammert, Alena Welters, Silke Otter, Jan Marquard, Thomas Meissner, Diran Herebian, Ertan Mayatepek
  • Patent number: 10464936
    Abstract: Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 5, 2019
    Assignee: Xoc Pharmaceuticals, Inc.
    Inventors: Thomas Armer, Geoff McKinley, Scott Borland, Miguel Guzman, Ármin Szabolcs, János Gerencser
  • Patent number: 10457627
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 29, 2019
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10456375
    Abstract: Biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, opthamological or urological disorders are provided as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 29, 2019
    Assignee: Biolitec Unternehmensbeteiligungs II AG
    Inventors: Hartwig Richard Arthur Golf, Arno Wiehe, Susanna Graefe, Volker Albrecht, Hans-Ulrich Reißig
  • Patent number: 10454037
    Abstract: Disclosed are a novel semiconductor composition comprising at least one organic semiconductor in a liquid medium and the use thereof the production of organic semiconductor devices, in particular organic field effect transistors, organic solar cells, light-emitting diodes and sensors.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 22, 2019
    Assignee: BASF SE
    Inventors: Ilja Vladimirov, Jochen Brill, Dieter Freyberg, Thomas Weitz, Thomas Musiol, Silke Annika Koehler
  • Patent number: 10441661
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 15, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K Martin, Bindu Bera
  • Patent number: 10435565
    Abstract: Novel red methine dyes, methods for the preparation thereof, and use thereof for dyeing plastics, especially vinyl polymers, provide red colourings with improved colour strengths and improved colour brilliance.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: October 8, 2019
    Assignee: LANXESS Deutschland GmbH
    Inventors: Hans-Ulrich Borst, Stephan Michaelis, Frank Linke
  • Patent number: 10428057
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: October 1, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Gang Liu, Kang Le, Jason Cross, Philip Jones
  • Patent number: 10421740
    Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 24, 2019
    Assignee: Syngenta Participations AG
    Inventors: Pierre Joseph Marcel Jung, Michel Muehlebach, Andrew Edmunds, Girish Rawal, Vikas Sikervar, Jagadish Pabba
  • Patent number: 10421743
    Abstract: A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from the group consisting of H, halo, C1-4 alkoxy, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH—C1-4 alkyl and cyano; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2e is H or Me; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl; wherein when R2e is H, at least one of R1a, R1b, R1c and R1d is selected from C1-4 alkoxy, C2-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH—C1-4 alkyl and cyano.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 24, 2019
    Assignee: CTXT PTY LTD
    Inventors: Ylva Elisabet Bergman, Michelle Ang Camerino, Scott Raymond Walker, Paul Anthony Stupple
  • Patent number: 10414732
    Abstract: The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 17, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Amanda Buist, Eden Fucci, Stephen G. Machatha, Osama Suleiman, Kate Wittering
  • Patent number: 10414778
    Abstract: The present disclosure describes a method to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds of the invention can decrease the rate of proliferation of drug-resistant cancer cells, such as glioma, lung cancer, and uterine sarcoma.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: September 17, 2019
    Assignee: NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION
    Inventors: Snezna Rogelj, Liliya Frolova, Alexander Kornienko, Sean Henry
  • Patent number: 10414785
    Abstract: Iridium (III) complexes are described together with methods to prepare and use such complexes. Also described are devices that utilize the iridium (III) complexes.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 17, 2019
    Assignee: ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Jian Li, Eric Turner, Nathan J. Bakken
  • Patent number: 10407408
    Abstract: Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 10, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Seigo Ishibuchi, Kunio Saruta, Maiko Hamada, Nobuatsu Matoba, Tetsuji Matsudaira, Maki Seki, Akiko Tarao, Takashi Honjo, Shingo Ogata, Atsushi Kawata, Kenji Morokuma, Naoto Fujie, Yukio Aoyama
  • Patent number: 10407437
    Abstract: Provided herein are camptothecin derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, cancer using the compounds and pharmaceutical compositions disclosed herein.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: September 10, 2019
    Assignee: Los Gatos Pharmaceuticals, Inc.
    Inventors: Peter Langecker, Matthias Steiert, Toshiaki Hino, Jan Scicinksi, Kumarapandian Paulvannan
  • Patent number: 10407434
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 10, 2019
    Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10407451
    Abstract: Transition metal compounds, and specifically transition metal compounds having a tetradentate and/or pentadentate supporting ligand are described, together with methods for the preparation thereof and the use of such compounds as hydrogenation and/or hydrosilylation catalysts.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: September 10, 2019
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Ryan J. Trovitch, Tufan K. Mukhopadhyay, Raja Pal, Hagit Ben-Daat Levin, Tyler M. Porter, Chandrani Ghosh
  • Patent number: 10409869
    Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 10, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Patent number: 10399995
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful as a BACE1 inhibitor.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 3, 2019
    Assignee: Eli Lilly and Company
    Inventors: Steven James Green, Erik James Hembre, II, Dustin James Mergott
  • Patent number: 10403831
    Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 3, 2019
    Assignee: Universal Display Corporation
    Inventors: David Knowles, Chun Lin, Peter Mackenzie, Jui-Yi Tsai, Robert W. Walters, Scott Beers, Cory S. Brown, Walter Yeager